GlassScriptPhysician profile
Paul M Gallogly
NPI 1477500791
$71,634.50
in general payments reported to CMS, 2019-2025
14 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $613 · 2021: $1,179 · 2022: $16K · 2023: $26K · 2024: $4,565 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $3,045 · Travel and Lodging: $2,884 · Honoraria: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,980.00 |
| Food and Beverage | $3,045.13 |
| Travel and Lodging | $2,883.52 |
| Honoraria | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $63,508.06 | 2019-2025 | Vabysmo |
| US Retina LLC | $2,996.54 | 2019-2022 | |
| Alimera Sciences, INC. | $1,440.16 | 2022-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $1,215.91 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $546.26 | 2022-2025 | |
| Eyepoint US, INC. | $521.84 | 2022 | |
| Apellis Pharmaceuticals, INC. | $503.61 | 2022-2025 | Syfovre |
| Astellas Pharma US INC | $348.97 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $161.41 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $124.99 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Ivantis, INC | $99.20 | 2020 | |
| Mallinckrodt Hospital Products INC. | $98.48 | 2024 | Acthar |
| Allergan, INC. | $42.36 | 2021 | |
| Ani Pharmaceuticals, INC. | $26.71 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,523.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gallogly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.